The majority of the FLT3 inhibitors, which have been or are being evaluated in clinical trials show initial response, but patients often relapse with various FLT3 mutations (including secondary FLT3 mutations) and complete remission of AML is challenging [8,9,[14], [15], [16], [17]]. The gene discussed is FLT3; the disease is acute myeloid leukemia.